Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Total Liabilities

Latest as of September 2025: CN¥1.86 Billion CNY ≈ $272.82 Million USD

Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has total liabilities worth CN¥1.86 Billion CNY (≈ $272.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Suzhou Zelgen Biopharmaceuticals Co Ltd cash flow conversion to assess how effectively this company generates cash.

Suzhou Zelgen Biopharmaceuticals Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd to evaluate the company's liquid asset resilience ratio.

Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Total Liabilities

The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Gaon Cable KO:000500	Korea	₩791.47 Billion
Fujian Funeng Co Ltd SHG:600483	China	CN¥20.37 Billion
Companhia de Saneamento de Minas Gerais SA:CSMG3	Brazil	R$9.16 Billion
Sphere Entertainment Co. NYSE:SPHR	USA	$1.98 Billion
CNO Financial Group Inc NYSE:CNO	USA	$36.09 Billion
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥1.60 Billion
Chipbond Technology TWO:6147	Taiwan	NT$6.86 Billion
Transcend Information Inc TW:2451	Taiwan	NT$3.21 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Suzhou Zelgen Biopharmaceuticals Co Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.62	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suzhou Zelgen Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)

The table below shows the annual total liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.75 Billion ≈ $256.37 Million	+41.02%
2023-12-31	CN¥1.24 Billion ≈ $181.80 Million	+41.05%
2022-12-31	CN¥880.82 Million ≈ $128.89 Million	+78.71%
2021-12-31	CN¥492.88 Million ≈ $72.12 Million	+76.85%
2020-12-31	CN¥278.69 Million ≈ $40.78 Million	+13.05%
2019-12-31	CN¥246.52 Million ≈ $36.07 Million	+42.30%
2018-12-31	CN¥173.24 Million ≈ $25.35 Million	+132.21%
2017-12-31	CN¥74.61 Million ≈ $10.92 Million	+168.71%
2016-12-31	CN¥27.76 Million ≈ $4.06 Million	--

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology

Market Cap

$4.11 Billion

CN¥28.06 Billion CNY

Market Cap Rank

#4116 Global

#715 in China

Share Price

CN¥106.02

Change (1 day)

+1.94%

52-Week Range

CN¥75.75 - CN¥133.48

All Time High

CN¥133.48